Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427476 · ClinicalTrials.gov registry record · Phase 1
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
A Phase 1 study, sponsored by Cancer Targeted Technology.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03427476: Completed Phase 1 study, sponsored by Cancer Targeted Technology.
NCT03427476 is a Phase 1 study that has completed, run by Cancer Targeted Technology. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03427476, a Phase 1 study, has completed, sponsored by Cancer Targeted Technology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.
Interventions
- DRUG CTT1057
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 1 |
What the finished NCT03427476 record still lists
NCT03427476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which CTT1057 is the first listed.
NCT03427476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03427476 about?
NCT03427476 is a clinical study titled "CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma". The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.
What is the current status of trial NCT03427476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-01-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT03427476?
The interventions under investigation include: CTT1057 (DRUG).
Who is sponsoring clinical trial NCT03427476?
This trial is sponsored by Cancer Targeted Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03427476's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI